Robert Gish, MD
, Medical Director, Hepatitis B Foundation and
Grace Wang, MD, MPH
, Family Physician, International Community Health Services
Because hepatitis B reactivation can occur alongside direct acting antiviral treatment for hepatitis C, the FDA has now issued a black box warning for individuals beginning treatment. This presents new obstacles for providers and patients in attempting to prevent HBV reactivation and the negative health outcomes associated with it.
Read the full article